{"nctId":"NCT02055872","briefTitle":"Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial","startDateStruct":{"date":"2014-09"},"conditions":["Edema","Hypoproteinemia"],"count":46,"armGroups":[{"label":"Intravenous albumin","type":"EXPERIMENTAL","interventionNames":["Drug: Intravenous albumin"]},{"label":"Normal saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal saline"]}],"interventions":[{"name":"Intravenous albumin","otherNames":[]},{"name":"Normal saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hemodynamically stable for at least 24 hours (absence of persistent \\[\\>1 h\\] hypotension \\[systolic blood pressure \\<90 mmHg), not currently on vasopressors, less than 2 L crystalloid or colloid boluses, or 2 units red blood cells administered, maintenance fluids excluded\n* Hypoproteinemia (serum albumin \\<30 mg/L or total protein \\< 60 mg/L)\n* Clinical decision to diurese at least 3 L net fluid balance within the next 72 hours for any reason\n\nExclusion Criteria:\n\n* known pregnancy\n* patient or surrogate unable or unwilling to consent to blood product administration, including albumin\n* history of adverse reactions or allergy to either albumin or furosemide\n* acute kidney injury (RIFLE criteria \"F\" or greater) without any improvement in past 24 hours, or otherwise expected to necessitate dialysis within 48 hours in opinion of treating physician\n* chronic kidney injury requiring dialysis\n* clinically documented cirrhosis\n* clinically documented nephrotic syndrome\n* serum sodium greater than 150 milliequivalent/L or serum potassium less than 2.5 mEq/L that connote be treated prior to administration of study treatment\n* inability to measure urine output and fluid balance\n* Receipt of hyperoncotic albumin within preceding 24 hours\n* previous enrollment in this trial, or any research studies which may interfere with this study\n* estimated survival or ICU stay less than 72 hours","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ventilator-free Days","description":"Ventilator-free days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Albumin and Colloid Osmotic Pressure","description":"Changes in serum albumin and serum colloid osmotic pressure measurements from Day 1, Day 3, Day 5","classes":[]},{"type":"SECONDARY","title":"Mortality","description":"Total ICU mortality and mortality at 30 days.","classes":[]},{"type":"SECONDARY","title":"Fluid Balance and Body Weight","description":"Change in total fluid balance and body weight from baseline at 3 days and 5 days","classes":[]},{"type":"SECONDARY","title":"Oxygenation","description":"Changes in oxygenation (FiO2, P/F ratio, oxygenation index) from baseline at day 3 and day 5","classes":[]},{"type":"SECONDARY","title":"Treatment Interruptions","description":"Number of episodes of interrupting treatment with furosemide (eg. hypotensive episodes, renal failure, contraction alkalosis, etc.)","classes":[]},{"type":"SECONDARY","title":"Duration of Mechanical Ventilation","description":"Total duration of mechanical ventilation","classes":[]},{"type":"SECONDARY","title":"Length of ICU Stay","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Adherence to Protocol","description":"The administration of at least the first dose of study treatment (albumin or placebo) within two hours of the first administration of furosemide","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Completion of Study Treatment","description":"Patients receiving full 72 hours (6 doses) of study treatment","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Absence of Co-intervention","description":"Absence of hyperoncotic albumin administration to patients randomized to the control arm","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Randomization Rate","description":"1. Randomization rate of patients eligible by screening criteria\n2. Randomization rate of patients eligible by clinical site","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Hypotension"]}}}